Inhibits activation of MAP kinase. Also anti-inflammatory and anti-secretory.Parthenolide Inhibits TNF/IL-1 or TNFInduced Production of IL-81.Parthenolide Inhibits I B Kinase, NF- B Activation, and Inflammatory Response in Cystic Fibrosis Cells and Mice. NF-B inhibitor parthenolide and the COX-2 inhibitor NS398 each inhibited hepatocellular carcinoma growth in a concentration-dependent manner. In addition, the combination of parthenolide and NS398 reduced the concentration of NS398 required to inhibit hepatocellular carcinoma growth.Parthenolide Cooperates with NS398 to Inhibit Growth of Human Hepatocellular Carcinoma Cells through Effects on Apoptosis and G-G Cell Cycle Arrest. Nuclear Factor- B Inhibition by Parthenolide Potentiates the Efficacy of Taxol in NonSmall Cell Lung Cancer.The NF-B inhibitor, parthenolide, may enhance chemosensitivity to paclitaxel in the treatment of patients with gastric cancer. Enhances Response to Chemotherapy in Gastric Cancer. Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions.

Additional Information

Product #	P-1233
CAS #	20554-84-1
Chemical Name	4,5-ALPHA-EPOXY-6BETA-HYDROXYGERMACRA-1(10),11(13)-DIEN-12-OIC ACID-GAMMA-LACTONE
Formula	C15H20O3
MW	248.3
Appearance	White Solid
Purity	98%
Solubility	Soluble in Ethyl Acetate and DMSO
Melting Point	118-120‚°C
Storage Temp	-20°C
Therapeutic Area	Oncological Disorders
Use	Parthenolide shows anticancer activity against human melanoma cells

Additional Information

MDL Number	MFCD00134592
ChemACX	X1017283-1
InChI	InChI=1S/C15H20O3/c1-9-5-4-8-15(3)13(18-15)12-11(7-6-9)10(2)14(16)17-12/h5,11-13H,2,4,6-8H2,1,3H3/b9-5-
SMILES	C/C/1=C/CCC2(C(O2)C3C(CC1)C(=C)C(=O)O3)C